Who mentions $SNY most on Surfaced?

@jacobplieth (Jacob Plieth) mentions $SNY most — 11 mentions in the past 12 months.

When was $SNY first mentioned on Surfaced?

The earliest tracked mention of $SNY in the Surfaced archive was on Jun 20, 2025.

How many voices track $SNY?

2 FinTwit voices have mentioned $SNY 18 times in the past 12 months.

What kind of voices mention $SNY most?

$SNY is mentioned most by Biotech voices on Surfaced.

$SNY — FinTwit mentions on Surfaced

Recent mentions

18 mentions

@jacobpliethFeb 12, 2026 · 2:30 PM

$SNY deserves congratulations for finding a new CEO whose track record makes Paul Hudson look good. Chapeau! https://t.co/m5qTqh6Pm5

Open on X

@adamfeuersteinFeb 12, 2026 · 10:48 AM

Paul Hudson out as Sanofi $SNY CEO https://t.co/HSxdB1PshV via @DrewQJoseph

Open on X

@jacobpliethFeb 4, 2026 · 10:35 AM

Some revelations for ADC nerds: $SNY uses the same MAb in its new CEACAM5 ADC as in the one it discontinued in 2023. Chia Tai claims a deuterated DXd payload (with no link to $DSNKY?). $DSNKY TA-MUC1 ADC uses sacomitatug, not Glycotope's gatipotuzumab.

Open on X

@jacobpliethJan 29, 2026 · 3:22 PM

Looks like $SNY discontinued Alphamedix/ SAR447873, licensed in Sep 2024 from Radiomedix & Orano Med, h/t B Riley. @ByMadeleineA covered it at #Esmo25 and flagged dysphagia & renal tox. https://t.co/6L2O0c5cOA Good news for $CATX?

Open on X

@adamfeuersteinJan 23, 2026 · 2:51 PM

Leerink's David Risinger on the $SNY amlitelimab Karposi's sarcoma case: "As a result, we see risk of a potential black box warning on amlitelimab’s label." Would be same for $AMGN $APGE and any other company with an OX40 drug, right?

Open on X

@adamfeuersteinJan 23, 2026 · 12:23 PM

Perhaps I am over-reacting, but doesn't the reported case of Kaposi's sarcoma in the $SNY amlitelimab atopic dermatitis study basically end any hope for the entire OX40 drug class? $AMGN included. Why would any patient or physician take the risk with an OX40 drug when there are so many other better treatment options?

Open on X

@adamfeuersteinJan 15, 2026 · 1:22 PM

Is there a single person feeding La Lettre fake biotech takeover tips, or is this a group effort? The stock manipulation is brazen. First, we learn all the $ABVX $LLY French Ministry speculation was fake, now today it's $SNY $OCUL The story explains Sanofi's interest in "combination therapies" --> Dextenza + Dupixent? What the f--k? Dextenza is a tiny eye implant, Dupixent is an injectable. What are you combining? The La Lettre story doesn't even mention Axpaxli or the upcoming SOL-1 ph3 study readout. I think $OCUL is interesting and if SOL-1 hits, the company could be sold. In fact, I wrote that in early January given CEO Pravin Dugel's track record selling Iveric to Astellas. But, please, look at how $OCUL traded at the end of Wednesday.

Open on X

@adamfeuersteinDec 8, 2025 · 12:01 PM

Kymera $KYMR drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial https://t.co/W3m3dtydJR via @JonathanWosen $SNY $REGN

Open on X

@jacobpliethNov 19, 2025 · 2:23 PM

$GSK just followed $NVS $LLY $PFE & $SNY into myeloid cell engagers. LTZ tech seems to do this via activity at CLEC5A

Open on X

@jacobpliethNov 19, 2025 · 11:54 AM

$COGT investor emphasis shifting away from mastocytosis? 95% of #Jefferies25 presentation was on 2L GIST $SNY https://t.co/NtJzAj09ke

Open on X

@jacobpliethOct 10, 2025 · 11:54 AM

So basically $SNY is a pioneer https://t.co/mth5czlAgv

Open on X

@jacobpliethOct 10, 2025 · 11:19 AM

Now $BMY buys Orbital for... $1.5bn! Focus seems to be autoimmune, but pipeline also includes some oncology work $AZN $ABBV $GILD $SNY $ALPMF https://t.co/rHXCOm2idI

Open on X

@jacobpliethSep 19, 2025 · 2:17 PM

$BMY confirms that it scrapped its 2017 NK-cell engager tie-up with Dragonfly. With $SNY $IPHA $AFMD $GTBP setbacks this modality looks like it's on borrowed time. Via @ApexOnco -> https://t.co/OCBrFB8P1P $MRK $ABBV $GILD

Open on X

@adamfeuersteinSep 4, 2025 · 10:37 AM

Sanofi $SNY shares drop after disappointing trial results. Amlitelimab falls short against Dupixent in atopic dermatitis. https://t.co/SJNDXMIIKd via @DrewQJoseph

Open on X

@adamfeuersteinJul 22, 2025 · 10:07 AM

Sanofi $SNY to buy vaccine biotech Vicebio for $1.15B upfront https://t.co/Vn6nfm792T via @DrewQJoseph

Open on X

@jacobpliethJul 7, 2025 · 6:07 PM

$COGT +25% as bezuclastinib safety remains in the spotlight. Via @ApexOnco -> https://t.co/c7zw3W4G5z $BPMC $SNY https://t.co/pgZlpoFn43

Open on X

@jacobpliethJun 20, 2025 · 4:48 PM

@phoenicianstrat @TerryMSmith @Sanctuary_Bio TBH I thought the two scales were pretty similar. I meant more about % chg from baseline / absolute chg adjusted for placebo / >50% chg, and general vagueness about the precise endpoint of Summit part 2 $COGT $BPMC $SNY

Open on X

@jacobpliethJun 20, 2025 · 3:43 PM

I know that $COGT has done everything possible to muddy the endpoints, so is this basically the state of play in Summit trial vs $BPMC $SNY Ayvakit? https://t.co/XKDbXKZYDF

Open on X

$SNY

$SNY

Frequently asked

Related stocks